Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Ophthalmology | Conference News

Back to Journal Articles

AAO: Microstent Cuts Intraocular Pressure in Glaucoma

Last Updated: November 13, 2012.

 

Decrease in pressure maintained at one year in mild-to-moderate open-angle glaucoma

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with mild-to-moderate open-angle glaucoma, implantation of a nickel titanium microstent (Hydrus Microstent) is associated with significant reduction in intraocular pressure, which is maintained at one year, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held from Nov. 10 to 13 in Chicago.

TUESDAY, Nov. 13 (HealthDay News) -- For patients with mild-to-moderate open-angle glaucoma, implantation of a nickel titanium microstent (Hydrus Microstent) is associated with significant reduction in intraocular pressure, which is maintained at one year, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held from Nov. 10 to 13 in Chicago.

Thomas W. Samuelson, M.D., from the University of Minnesota in Minneapolis, and colleagues assessed the ability of a microstent implanted ab interno in the Schlemm canal to lower intraocular pressure in a cohort of 69 patients from six centers who were suffering from mild-to-moderate open-angle glaucoma. The Hydrus stent was placed during cataract surgery in 40 patients, while 29 patients had the stent placed without cataract surgery. Prior to surgery and at one-year follow-up, patients were washed out of glaucoma medications.

The researchers found that, at six months, 85 percent of combined surgery and 70 percent of stent-only patients no longer needed medication to control their intraocular pressure. In 40 treated patients there was a significant reduction in the mean intraocular pressure from baseline to one year (23.8 ± 3.5 to 18.0 ± 4.6).

"So far, mini-stents appear to have important advantages in that they allow us to treat open-angle glaucoma at earlier stages and with lower complication risk," Samuelson said in a statement. "If the devices can effectively control intraocular pressure over many years, it would be a real breakthrough in combating this blinding disease."

The study was funded by Ivantis, the manufacturer of the Hydrus Microstent.

Press Release
More Information

Copyright © 2012 HealthDay. All rights reserved.


Previous: Lack of Resources ID'd in Peds Concussion Management Next: Dance Improves Self-Rated Health for Teen Girls

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.